Treatment of Pineoblastoma with Drop Metastases
For patients ≥3 years with metastatic pineoblastoma (including drop metastases), treat with craniospinal irradiation (CSI) 36 Gy plus tumor bed boost (up to 54 Gy) followed by embryonal-type maintenance chemotherapy, with or without pre-radiotherapy chemotherapy. 1
Age-Based Treatment Algorithm
Patients ≥3 Years Old with Metastatic Disease
The 2024 SNO-EANO-EURACAN consensus provides clear guidance for this high-risk population 1:
Two acceptable treatment sequences:
CSI 36 Gy + tumor bed boost (up to 54 Gy) → embryonal-type maintenance chemotherapy (high-risk protocols)
Pre-RT chemotherapy → CSI 36 Gy + tumor bed boost (up to 54 Gy) → embryonal-type maintenance chemotherapy
The evidence shows that metastatic disease confers 2-3 fold higher relapse risk and inferior 5-year overall survival of 50-55% despite intensive therapy 1. Multiple trials (CCG-99701, COG ACNS0332) using 36 Gy CSI with concurrent vincristine and carboplatin followed by standard-dose chemotherapy have demonstrated 5-year progression-free survival of approximately 62% 1.
Critical point: The role of pre-irradiation chemotherapy remains unclear. While HIT-91 suggested pre-chemotherapy radiation increases metastatic progression, this was not confirmed in pooled European-Head Start cohorts 1. However, the SIOPE approach for high-risk medulloblastoma using pre-RT chemotherapy requires further evaluation in pineoblastoma.
Patients <3 Years Old with Metastatic Disease
No standard regimen exists for this age group 1. The evidence is uniformly dismal:
- High-dose chemotherapy-containing regimens should be considered
- Focal RT may be considered in localized disease, though evidence is extremely limited
- CSI may benefit a proportion of very high-risk patients based on HIT 2000 data showing 2/3 survival in young metastatic cases who received CSI after incomplete response to induction 1
Major caveat: Outcomes in children <3 years are catastrophic. The Baby POG trial showed 100% mortality by 13 months with standard-dose chemotherapy alone 1. The SJYC07 trial reported only 14% 2-year progression-free survival despite risk-adapted therapy 1. Head Start I-III trials using high-dose chemotherapy with autologous stem-cell rescue showed 5-year progression-free survival of only 9.7% 1.
Molecular Subtype Considerations
While the guideline recommendations are primarily age-based, molecular subtypes have prognostic implications 1:
- PB-MYC/FOXR2 and PB-RB1 subgroups: Almost exclusively in infants/young children with dismal outcomes (5-year OS: 24% and 30% respectively)
- PB-miRNA1/2 subgroups: Occur in older children with better outcomes (5-year OS: 70% and 100% respectively)
Important: Nearly 70% of failures in PB-miRNA1 patients were distant and often late, suggesting need for therapy extension and improved targeting of metastatic disease 1.
Surgical Considerations
Maximal safe resection should be attempted when feasible, though extent of resection may not significantly impact survival in patients receiving intensive multimodal therapy 1. Complete staging with preoperative neuroaxis MRI and CSF cytology (obtained 10-14 days post-surgery) is critical 1.
Key Pitfalls to Avoid
- Do not use reduced-dose CSI (23.4 Gy) in metastatic disease - this is only appropriate for localized disease in favorable molecular subtypes 1
- Do not delay radiotherapy indefinitely in young children - radiation-sparing approaches have universally failed 1
- Do not use focal RT alone in metastatic disease - even in young children, the high metastatic potential demands craniospinal coverage when RT is given 2